Consensus Arvinas, Inc.

Stocks

ARVN

US04335A1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:36:34 2026-09-04 EDT			5-day change	1st Jan Change
9.365 ^USD	+0.59%		+1.94%	-21.09%

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating	MT

Evolution of the Average Target: Arvinas, Inc.

Evolution of the Target Price: Arvinas, Inc.

Changes in Analyst Recommendations: Arvinas, Inc.

0809a92933f2ebf331d78.lMuV9DdJp-hqIRa62eHMexyPoOdvbdNbkiQfr8NMj2E.wK7ZxFMwkdgaGXLvttSvNi_u0qkJF-BipxFtmbEOyyulvqaWQ3uV2yt0Qw~c842b41bbbe53b7a1dcad94790763bf4

Analysts' recommendations: Arvinas, Inc.

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating	MT
08-04	Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating	MT
05-14	BofA Securities Raises Price Target on Arvinas to $16 From $14	MT
02-24	Wedbush Lifts Price Target on Arvinas to $11 From $9, Keeps Neutral Rating	MT
01-06	Citigroup Upgrades Arvinas to Buy From Neutral, Adjusts Price Target to $15 From $10	MT
25-10-20	Arvinas, Inc. Announces New Patient-Reported Outcomes Data from the Phase 3 Veritac-2 Clinical Trial Evaluating Vepdegestrant	CI
25-10-15	Goldman Sachs Downgrades Arvinas to Sell From Neutral, Cuts Price Target to $6 From $8	MT
25-09-18	Wedbush Cuts Price Target on Arvinas to $9 From $10, Keeps Neutral Rating	MT
25-08-08	Truist Cuts Price Target on Arvinas to $10 From $11, Keeps Hold Rating	MT
25-08-07	Wedbush Cuts Price Target on Arvinas to $10 From $12, Keeps Neutral Rating	MT
25-08-07	Morgan Stanley Lowers Price Target on Arvinas to $10 From $11, Keeps Equalweight Rating	MT
25-08-06	Arvinas Q2 revenue falls 71%, net loss widens	RE
25-05-15	UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating	MT
25-05-09	Morgan Stanley Cuts Price Target on Arvinas to $11 From $12, Keeps Equalweight Rating	MT
25-05-05	Truist Downgrades Arvinas to Hold From Buy, Cuts Price Target to $11 From $21	MT
25-05-02	Jefferies Downgrades Arvinas to Hold From Buy, Adjusts Price Target to $10 From $52	MT
25-05-02	TD Cowen Downgrades Arvinas to Hold From Buy	MT
25-04-09	Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating	MT
25-03-13	Goldman Sachs Downgrades Arvinas to Neutral From Buy, Cuts Price Target to $15 From $70	MT
25-03-12	Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57	MT
25-03-11	Citigroup Cuts Arvinas' Price Target to $10 From $19, Maintains Neutral Rating	MT
25-03-11	Oppenheimer Downgrades Arvinas to Perform From Outperform	MT
25-02-12	Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating	MT
24-10-31	UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARVINAS, INC.					+49.61%
	WUXI APPTEC CO., LTD.					+18.92%
	ARGENX SE					+9.64%
	INSMED INCORPORATED					+58.02%
	BIONTECH SE					+16.97%
	WUXI BIOLOGICS (CAYMAN) INC.					+13.1%
	GENMAB A/S					+10.47%
	PHARMAESSENTIA CORPORATION					+3.5%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+24.48%
	EXELIXIS, INC.					-9.2%
	Average					+19.55%
	Weighted average by Cap.					+17.19%